# A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

> **NCT01290900** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 54 (actual)

## Conditions studied

- Healthy Male Volunteers

## Interventions

- **DRUG:** NXL104
- **DRUG:** Ceftaroline
- **DRUG:** Placebo Infusion
- **DRUG:** Ceftazidime
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01290900
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01290900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01290900, "A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01290900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*